Targeted agents, such as Bruton’s Tyrosine Kinase inhibitors and BCL-2 inhibitors, have transformed the treatment landscape for Chronic Lymphocytic Leukemia (CLL). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.